Knight Therapeutics Expands Hematology Portfolio with TAVALISSE Launch in Brazil
Event summary
- Knight Therapeutics launched TAVALISSE® in Brazil for chronic immune thrombocytopenia (ITP) on October 6, 2026.
- TAVALISSE® is the second hematology product in Knight’s Brazilian portfolio, alongside MINJUVI®.
- Knight secured exclusive Latin American commercialization rights for TAVALISSE® from Rigel Pharmaceuticals in May 2022.
- Regulatory approvals obtained in Mexico (2024), Brazil (May 2026), and Colombia (September 2026).
- TAVALISSE® is an orally administered spleen tyrosine kinase (SYK) inhibitor.
The big picture
Knight Therapeutics continues to strengthen its hematology and oncology portfolio in Latin America, leveraging its regional commercialization expertise. The launch of TAVALISSE® in Brazil follows a strategic pattern of securing exclusive rights to innovative therapies and expanding access across key markets. This move aligns with broader industry trends of regional specialization in pharmaceutical distribution and the growing demand for targeted hematology treatments.
What we're watching
- Regulatory Progress
- The pace at which Knight secures approvals in Argentina and Paraguay will determine the speed of further Latin American expansion.
- Market Penetration
- Whether TAVALISSE® can gain significant market share against existing ITP treatments in Brazil.
- Portfolio Synergy
- How the addition of TAVALISSE® will impact the commercial performance of MINJUVI® in Brazil.
Related topics